Supportive treatments

Mobilization of Hematopoietic Progenitor Cells with Standard or Reduced Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients. a Randomized Prospective Single Center Phase II Study. Samaras P et al. Biol Blood Marrow Transplant. 2017 Dec 12. pii: S1083-8791(17)31679-8. doi: 10.1016/j.bbmt.2017.12.775. [Epub ahead of print]. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.…

Details

Related conditions

Pattern of care and impact of prognostic factors on the outcome of head and neck extramedullary plasmacytoma: a systematic review and individual patient data analysis of 315 cases. Venkatesulu B et al. Eur Arch Otorhinolaryngol. 2017 Dec 9. doi: 10.1007/s00405-017-4817-z. [Epub ahead of print]. Case Report: Treatment of Light Chain Amyloidosis with Daratumumab Monotherapy in Two Patients. Gran…

Details

General

Falls in Older Adults with Multiple Myeloma. Wildes TM et al. Eur J Haematol. 2017 Dec 14. doi: 10.1111/ejh.13009. [Epub ahead of print]. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations From the Organizing Committee. Holstein SA et al. Biol Blood Marrow Transplant. 2017 Dec 11. pii: S1083-8791(17)31678-6. doi: 10.1016/j.bbmt.2017.12.774. [Epub ahead of print]. Multiple Myeloma and Bone:…

Details

Emerging treatments

A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma. Ri M et al. Intern Med. 2017 Dec 8. doi: 10.2169/internalmedicine.9567-17. [Epub ahead of print]. Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. Meyers DE et al. Blood Cancer J. 2017 Dec 5;7(12):640. doi: 10.1038/s41408-017-0020-0.…

Details

Diagnostic techniques and prognostic indicators

Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient. Sachpekidis C et al. Diagnostics (Basel). 2017 Dec 15;7(4). pii: E61. doi: 10.3390/diagnostics7040061. Predictive value of 18 F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma. Tu…

Details

Current treatments

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. Mateos MV et al. N Engl J Med. 2017 Dec 12. doi: 10.1056/NEJMoa1714678. [Epub ahead of print]. Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Auner HW et al. Haematologica. 2017…

Details

Complications of myeloma and its treatments

Gastric submucosal haematoma caused by an amyloidoma in the setting of multiple myeloma. Pak SC et al. Arab J Gastroenterol. 2017 Dec 14. pii: S1687-1979(17)30116-8. doi: 10.1016/j.ajg.2017.12.002. [Epub ahead of print]. A case of Multiple Myeloma presenting with diffuse osteosclerosis and multiple bone infarcts. Vignon M et al. Joint Bone Spine. 2017 Dec 9. pii: S1297-319X(17)30203-8. doi: 10.1016/j.jbspin.2017.11.013. [Epub ahead of print]. Systolic dysfunction associated…

Details

Biology and genetics

DNA damage response-initiated cytokine secretion in bone marrow stromal cells promotes chemoresistance of myeloma cells. Tang H et al. Leuk Lymphoma. 2017 Dec 18:1-7. doi: 10.1080/10428194.2017.1413188. [Epub ahead of print]. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Zhou L et al. Br J Cancer. 2017 Dec 14. doi: 10.1038/bjc.2017.432. [Epub ahead of print]. Jagged1-induced Notch activation contributes to…

Details